{"DataElement":{"publicId":"2775782","version":"1","preferredName":"Hematopoietic Growth Factor Or Cytokine Pharmacologic Substance Type","preferredDefinition":"A description of the hematopoietic growth factor or cytokines.","longName":"HGF_OR_CTK_PHRM_S_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2775773","version":"1","preferredName":"Hematopoietic Growth Factor Or Cytokine Pharmacologic Substance Type","preferredDefinition":"Endogenous growth factors which promote the development of blood cells._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A class of soluble glycoproteins which act nonenzymatically through specific receptors to regulate immune responses. Cytokines are derived from both immune and non-immune cells and are intercellular mediators that differ from hormones in that they are produced by a number of tissue or cell types rather than by specialized glands._An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b))._Something distinguishable as an identifiable class based on common qualities.","longName":"HGF_OR_CTK_PHRM_TP","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2775771","version":"1","preferredName":"Hematopoietic Growth Factor Or Cytokine Pharmacologic Substance","preferredDefinition":"Endogenous growth factors which promote the development of blood cells.:Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Cytokines are a unique family of growth factors. Secreted primarily from leukocytes, cytokines stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells. Cytokines that are secreted from lymphocytes are termed lymphokines, whereas those secreted by monocytes or macrophages are termed monokines. A large family of cytokines are produced by various cells of the body. Many of the lymphokines are also known as interleukins (ILs), since they are not only secreted by leukocytes but also able to affect the cellular responses of leukocytes. Specifically, interleukins are growth factors targeted to cells of hematopoietic origin. (http://indstate.edu/thcme/mwking/growth-factors):A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.","longName":"C20427:C37998:C20464:C1909","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Growth Factor","conceptCode":"C20427","definition":"Endogenous growth factors which promote the development of blood cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytokine","conceptCode":"C20464","definition":"A class of soluble glycoproteins which act nonenzymatically through specific receptors to regulate immune responses. Cytokines are derived from both immune and non-immune cells and are intercellular mediators that differ from hormones in that they are produced by a number of tissue or cell types rather than by specialized glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FD304E-0678-39FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-21","modifiedBy":"ONEDATA","dateModified":"2008-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FD304E-0686-39FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2796009","version":"1","preferredName":"Hematopoietic Growth Factor Or Cytokine Pharmacologic Substance Type","preferredDefinition":"Endogenous growth factors which promote the development of blood cells._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A class of soluble glycoproteins which act nonenzymatically through specific receptors to regulate immune responses. Cytokines are derived from both immune and non-immune cells and are intercellular mediators that differ from hormones in that they are produced by a number of tissue or cell types rather than by specialized glands._An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b))._Type; a subdivision of a particular kind of thing.","longName":"HGF_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"66","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Blinded growth factor or cytokine trial","valueDescription":"Hematopoietic Growth Factor Or Cytokine Blinded Clinical Study","ValueMeaning":{"publicId":"2796010","version":"1","preferredName":"Hematopoietic Growth Factor Or Cytokine Blinded Clinical Study","longName":"2796010","preferredDefinition":"Endogenous growth factors which promote the development of blood cells.: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Cytokines are a unique family of growth factors. Secreted primarily from leukocytes, cytokines stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells. Cytokines that are secreted from lymphocytes are termed lymphokines, whereas those secreted by monocytes or macrophages are termed monokines. A large family of cytokines are produced by various cells of the body. Many of the lymphokines are also known as interleukins (ILs), since they are not only secreted by leukocytes but also able to affect the cellular responses of leukocytes. Specifically, interleukins are growth factors targeted to cells of hematopoietic origin. (http://indstate.edu/thcme/mwking/growth-factors): A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Growth Factor","conceptCode":"C20427","definition":"Endogenous growth factors which promote the development of blood cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytokine","conceptCode":"C20464","definition":"A class of soluble glycoproteins which act nonenzymatically through specific receptors to regulate immune responses. Cytokines are derived from both immune and non-immune cells and are intercellular mediators that differ from hormones in that they are produced by a number of tissue or cell types rather than by specialized glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Blinded Clinical Study","conceptCode":"C70840","definition":"A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A6A0AA6-18E9-3FF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A6A0AA6-1902-3FF5-E044-0003BA3F9857","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"NYCHM","dateModified":"2008-10-29","deletedIndicator":"No"},{"value":"Velafermin","valueDescription":"Velafermin","ValueMeaning":{"publicId":"2769628","version":"1","preferredName":"Velafermin","longName":"2769628","preferredDefinition":"A recombinant human fibroblast growth factor-20 (rhFGF-20) protein with pro-proliferative activity.  Velafermin stimulates DNA synthesis and cell proliferation, specifically promoting epithelial and mesenchymal cell proliferation, and may prevent radiation or chemotherapy-induced oral mucositis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Velafermin","conceptCode":"C48425","definition":"A recombinant human fibroblast growth factor-20 (rhFGF-20) protein with pro-proliferative activity.  Velafermin stimulates DNA synthesis and cell proliferation, specifically promoting epithelial and mesenchymal cell proliferation, and may prevent radiation or chemotherapy-induced oral mucositis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53415CE1-97E4-4013-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A6A0AA6-1917-3FF5-E044-0003BA3F9857","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"NYCHM","dateModified":"2008-10-29","deletedIndicator":"No"},{"value":"Erythropoietin","valueDescription":"Recombinant Erythropoietin","ValueMeaning":{"publicId":"2796011","version":"1","preferredName":"Recombinant Erythropoietin","longName":"2796011","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Erythropoietin","conceptCode":"C477","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A6A0AA6-193A-3FF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A6A0AA6-1953-3FF5-E044-0003BA3F9857","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"NYCHM","dateModified":"2008-10-29","deletedIndicator":"No"},{"value":"GM-CSF","valueDescription":"GM-CSF","ValueMeaning":{"publicId":"2576458","version":"1","preferredName":"GM-CSF","longName":"2576458","preferredDefinition":"Granulocyte-macrophage colony-stimulating factor. A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called sargramostim.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","conceptCode":"C1288","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F7B7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-07","modifiedBy":"SHIDED","dateModified":"2013-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A6A0AA6-195F-3FF5-E044-0003BA3F9857","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"NYCHM","dateModified":"2008-10-29","deletedIndicator":"No"},{"value":"G-CSF","valueDescription":"Recombinant Granulocyte Colony Stimulating Factor","ValueMeaning":{"publicId":"2644084","version":"1","preferredName":"Recombinant Granulocyte Colony Stimulating Factor","longName":"2644084","preferredDefinition":"G-CSF. A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell).  It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called filgrastim.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Granulocyte Colony-Stimulating Factor","conceptCode":"C1287","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF).  Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31378E67-E6B9-69CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-24","endDate":null,"createdBy":"GUEST","dateCreated":"2007-05-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A6A0AA6-196B-3FF5-E044-0003BA3F9857","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"NYCHM","dateModified":"2008-10-29","deletedIndicator":"No"},{"value":"Other agent","valueDescription":"Other Pharmacologic Substance","ValueMeaning":{"publicId":"2775670","version":"1","preferredName":"Other Pharmacologic Substance","longName":"2775670","preferredDefinition":"Different than the one(s) previously specified or mentioned.: Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FB5BE0-0144-7379-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-08-21","modifiedBy":"MAESKEB","dateModified":"2018-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5DA32B68-6FEB-6DE5-E040-BB89A6431187","beginDate":"2008-12-09","endDate":null,"createdBy":"CDECURATE","dateCreated":"2008-12-09","modifiedBy":"CDECURATE","dateModified":"2008-12-09","deletedIndicator":"No"},{"value":"KGF","valueDescription":"Palifermin","ValueMeaning":{"publicId":"2769629","version":"1","preferredName":"Palifermin","longName":"2769629","preferredDefinition":"A recombinant form of the endogenous human keratinocyte growth factor with cell growth promoting activity. Palifermin acts in the manner similar to the endogenous keratinocyte growth factor that binds to keratinocyte growth factor receptors on the epithelial cell surface in the lining of mouth and gastrointestinal tract. This results in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palifermin","conceptCode":"C2455","definition":"A recombinant form of the endogenous human keratinocyte growth factor with cell growth promoting activity. Palifermin acts in the manner similar to the endogenous keratinocyte growth factor that binds to keratinocyte growth factor receptors on the epithelial cell surface in the lining of mouth and gastrointestinal tract. This results in stimulation of epithelial cell proliferation, differentiation and upregulation of cytoprotective mechanisms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"53415CE1-9809-4013-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CZECHS","dateCreated":"2008-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"76143614-8BB3-AE11-E040-BB89AD43462C","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-16","modifiedBy":"ONEDATA","dateModified":"2009-10-16","deletedIndicator":"No"},{"value":"None received","valueDescription":"None","ValueMeaning":{"publicId":"4001711","version":"1","preferredName":"None","longName":"4001711","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED6DCE6B-B411-EF30-E040-BB89AD4369A8","latestVersionIndicator":"Yes","beginDate":"2013-12-13","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-12-13","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEB1DBDD-5293-214F-E053-4EBD850AB9BD","beginDate":"2021-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-29","modifiedBy":"ONEDATA","dateModified":"2021-03-29","deletedIndicator":"No"},{"value":"Thrombopoietin","valueDescription":"Thrombopoietin","ValueMeaning":{"publicId":"7135787","version":"1","preferredName":"Thrombopoietin","longName":"7135787","preferredDefinition":"A substance made by the body that helps make blood cells, especially platelets. A form of TPO made in the laboratory is called recombinant human TPO and rHu TPO. TPO is being studied as a way to increase the number of platelets in cancer patients receiving chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thrombopoietin","conceptCode":"C20441","definition":"Thrombopoietin (353 aa, ~38 kDa) is encoded by the human THPO gene. This protein is involved in both megakaryocyte differentiation and platelet activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BBB8387-61B1-2284-E053-F662850A9CAB","latestVersionIndicator":"Yes","beginDate":"2020-01-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-09","modifiedBy":"ONEDATA","dateModified":"2020-01-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEB1DBDD-529D-214F-E053-4EBD850AB9BD","beginDate":"2021-03-29","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-03-29","modifiedBy":"ONEDATA","dateModified":"2021-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2796008","version":"1","preferredName":"Hematopoietic Growth Factor Or Cytokine Pharmacologic Substance Type","preferredDefinition":"Endogenous growth factors which promote the development of blood cells.:Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Cytokines are a unique family of growth factors. Secreted primarily from leukocytes, cytokines stimulate both the humoral and cellular immune responses, as well as the activation of phagocytic cells. Cytokines that are secreted from lymphocytes are termed lymphokines, whereas those secreted by monocytes or macrophages are termed monokines. A large family of cytokines are produced by various cells of the body. Many of the lymphokines are also known as interleukins (ILs), since they are not only secreted by leukocytes but also able to affect the cellular responses of leukocytes. Specifically, interleukins are growth factors targeted to cells of hematopoietic origin. (http://indstate.edu/thcme/mwking/growth-factors):A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.:Type; a subdivision of a particular kind of thing.","longName":"C20427:C37998:C20464:C1909:C25","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Growth Factor","conceptCode":"C20427","definition":"Endogenous growth factors which promote the development of blood cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Cytokine","conceptCode":"C20464","definition":"A class of soluble glycoproteins which act nonenzymatically through specific receptors to regulate immune responses. Cytokines are derived from both immune and non-immune cells and are intercellular mediators that differ from hormones in that they are produced by a number of tissue or cell types rather than by specialized glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A6A0AA6-18BE-3FF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"ONEDATA","dateModified":"2008-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A6A0AA6-18CF-3FF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-10-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-10-29","modifiedBy":"MALUMK","dateModified":"2021-03-29","changeDescription":".PVs added for 2100r7. 03/29/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964902","version":"1","longName":"2100r1: 100 Days Post-HSCT Data","context":"NHLBI"},{"publicId":"2964922","version":"1","longName":"2200r1: 6 Month to 2 Year Post-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"MaterialName:name","type":"HCT_BRIDG","context":"NHLBI"},{"name":"HPST_GFC_gf_cytokine_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Type(s) of s given:","type":"Preferred Question Text","description":"Type(s) of s given:","url":null,"context":"NHLBI"},{"name":"Type(s) of hematopoietic, lymphoid growth factor or cytokine agents given:","type":"Alternate Question Text","description":"Type(s) of hematopoietic, lymphoid growth factor or cytokine agents given:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2775782","type":"BRIDG Mapping Path","description":"PerformedProcedure > DefinedActivity > Product > MaterialName.name WHERE Product.typeCode = \"Hematopoietic Reconstitution\"","url":null,"context":"NHLBI"},{"name":"Specify hematopoietic, lymphoid growth factor or cytokine received","type":"Alternate Question Text","description":"Specify hematopoietic, lymphoid growth factor or cytokine received","url":null,"context":"NHLBI"},{"name":"Specify hematopoietic, lymphoid growth factor or cytokine received","type":"Application Standard Question Text","description":"Specify hematopoietic, lymphoid growth factor or cytokine received","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"54FD4DAA-CB71-4007-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-21","modifiedBy":"MALUMK","dateModified":"2021-10-04","changeDescription":". System generated def displayed as alt def. AK 6/10/15. AQT added for 2100r7. 03/29/2021 KMM. Added ASQT since it was missing. 06/29/2021 KMM. ALT name added for 2100r7. 10/04/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}